Zacks Research Analysts Lower Earnings Estimates for ALNY

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Zacks Research reduced their Q2 2025 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a note issued to investors on Monday, January 27th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings of ($0.97) per share for the quarter, down from their prior forecast of ($0.96). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.24) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($3.11) EPS, Q3 2026 earnings at $0.68 EPS, Q4 2026 earnings at $0.67 EPS and FY2026 earnings at $1.86 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.15 EPS.

ALNY has been the topic of several other reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, January 21st. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Bank of America upped their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $273.99 on Thursday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a market cap of $35.34 billion, a P/E ratio of -104.58 and a beta of 0.34. The firm’s 50 day moving average price is $249.42 and its 200 day moving average price is $260.65.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Huntington National Bank raised its holdings in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $29,000. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $33,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $42,000. Finally, True Wealth Design LLC boosted its position in Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at approximately $19,797,302.40. The trade was a 6.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,964 shares of company stock valued at $20,622,925 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.